GCP
BEAM icon

Gill Capital Partners’s Beam Therapeutics BEAM Stock Holding History

Gill Capital Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357 Buy
+15
New +$416 ﹤0.01% 647

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Gill Capital Partners's BEAM Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 15 shares worth $357. The stake represents ﹤0.01% of the portfolio and ranks #647 among its holdings.

251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Gill Capital Partners held 15 shares of Beam Therapeutics worth $357 as of Q1 2026.
  • Beam Therapeutics was a new Gill Capital Partners position in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #647 holding.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.